Clincelin, a redesigned and improved lincosamide
Novotná, M., Slavík, P., Demay, F., Mahor, D., Řeha, D., Boissier, F., Pokorná, J., Vimberg, V., Brajerová, M., Stefani, T., Svoboda, J., Gažák, R., März, M., Hošek, J., Koběrská, M., Eigner, V., Hanzlíková, L., Kuzma, M., Krůtová, M., Kameník, Z., Šigut, K., Janata, J., Innis, C.A., Balíková Novotná G. (2026) Clincelin: A redesigned lincosamide with enhanced intracellular accumulation and adaptive binding to resistant ribosomes. Research Square (preprint), rs-8873829, v1.
Lincosamide antibiotics block protein synthesis by binding the ribosome, but they’re losing ground to bacteria that carry Erm enzymes, which chemically modify the ribosome at A2058 and shut the drug out. In this collaborative study spearheaded by the Balíková Novotná lab, we present clincelin, a hybrid lincosamide that keeps the classic thiooctose core of lincosamides while combining a propylated proline from lincomycin, a salicylate group from celesticetin, and a clinically validated chlorine at C7. We find that the salicylate and chlorine work together to boost how much drug accumulates inside bacterial cells, making clincelin more potent than its parent compounds and clindamycin. Notably, it partially retains activity against erm-resistant pathogens: our cryo-EM structures show that the salicylate binds differently on normal versus A2058-dimethylated Staphylococcus aureus ribosomes, helping it get around the resistance mechanism. Ultimately, we hope that understanding how each structural modification affects function will guide the design of new antibiotics built to overcome existing resistance.



